Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Return on Sales (2019 - 2024)

Benitec Biopharma has reported Return on Sales over the past 6 years, most recently at 30.74% for Q1 2024.

  • Quarterly results put Return on Sales at 30.74% for Q1 2024, down 2993.0% from a year ago — trailing twelve months through Mar 2024 was 30.74% (down 2790.0% YoY), and the annual figure for FY2023 was 2.55%, down 10.0%.
  • Return on Sales reached 30.74% in Q1 2024 per BNTC's latest filing, down from 3.56% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.82% in Q2 2020 and bottomed at 39.34% in Q3 2021.
  • Median Return on Sales over the past 5 years was 2.72% (2023), compared with a mean of 10.91%.
  • The largest annual shift saw Return on Sales tumbled -3885bps in 2021 before it soared 3723bps in 2022.
  • Over 5 years, Return on Sales stood at 32.61% in 2020, then surged by 94bps to 1.94% in 2021, then plummeted by -107bps to 4.01% in 2022, then increased by 11bps to 3.56% in 2023, then tumbled by -763bps to 30.74% in 2024.
  • Business Quant data shows Return on Sales for BNTC at 30.74% in Q1 2024, 3.56% in Q4 2023, and 2.72% in Q3 2023.